
    
      For patients with high-risk lymphoid malignancies, patients will undergo allo-HSCT from HLA
      matched sibling, unrelated (9~10/10) donor or hallo-identical donors. For all patients will
      receive myeloablative conditioning with 5-day fludarabine, 2-day VP-16 and 3-day busulifan.
      For prophylaxis graft versus host disease (GVHD), patients will receive cyclophosphamide
      50mg/kg daily on D+3 and +4 with subsequent tacrolimus starting at D+5. For patients
      receiving HSCT from unrelated or haplo-donor, low-dose ATG 2.5mg/kg will be given on Day +15.
    
  